Page 91 - Read Online

Pippione et al. Steroidogenic enzymes in prostate cancer

CA, van Tol J, Ziel-van der Made AC, Brinkmann AO, Pike AC, androgen receptor antagonists. Arch Pharm (Weinheim) 2015;348:757-
Trapman J. Distinct recognition modes of FXXLF and LXXLL motifs 75.
by the androgen receptor. Mol Endocrinol 2004;18:2132-50. 126. Tice CM, Zheng YJ. Non-canonical modulators of nuclear receptors.
108. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z. Bioorg Med Chem Lett 2016;26:4157-64.
Identification and characterization of a ligand-regulated nuclear export 127. Lallous N, Dalal K, Cherkasov A, Rennie PS. Targeting alternative
signal in androgen receptor. J Biol Chem 2003;278:41998-2005. sites on the androgen receptor to treat castration-resistant prostate
109. Shang Y, Myers M, Brown M. Formation of the androgen receptor cancer. Int J Mol Sci 2013;14:12496-519.
transcription complex. Mol Cell 2002;9:601-10. 128. Kandil S, Westwell AD, McGuigan C. 7-Substituted umbelliferone
110. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate derivatives as androgen receptor antagonists for the potential treatment
cancer development and progression. J Carcinog 2011;10:20. of prostate and breast cancer. Bioorg Med Chem Lett 2016;26:2000-4.
111. Green SM, Mostaghel EA, Nelson PS. Androgen action and 129. Johnson JK, Skoda EM, Zhou J, Parrinello E, Wang D, O’Malley K,
metabolism in prostate cancer. Mol Cell Endocrinol 2012;360:3-13. Eyer BR, Kazancioglu M, Eisermann K, Johnston PA, Nelson JB,
112. Kahn B, Collazo J, Kyprianou N. Androgen receptor as a driver of Wang Z, Wipf P. Small molecule antagonists of the nuclear androgen
therapeutic resistance in advanced prostate cancer. Int J Biol Sci receptor for the treatment of castration-resistant prostate cancer. ACS
2014;10:588-95. Med Chem Lett 2016;7:785-90.
113. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone- 130. Balog A, Rampulla R, Martin GS, Krystek SR, Attar R, Dell-John J,
dependent and castration-resistant prostate cancer. Pharmacol Ther DiMarco JD, Fairfax D, Gougoutas J, Holst CL, Nation A, Rizzo C,
2013;140:223-38. Rossiter LM, Schweizer L, Shan W, Spergel S, Spires T, Cornelius
114. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, G, Gottardis M, Trainor G, Vite GD, Salvati ME. Discovery of BMS-
Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the 641988, a novel androgen receptor antagonist for the treatment of
androgen receptor promoter CpG island is associated with loss of prostate cancer. ACS Med Chem Lett 2015;6:908-12.
androgen receptor expression in prostate cancer cells. Cancer Res 131. Zhao C, Choi YH, Khadka DB, Jin Y, Lee KY, Cho WJ. Design
1998;58:5310-4. and synthesis of novel androgen receptor antagonists via molecular
115. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa modeling. Bioorg Med Chem 2016;24:789-801.
Y, Mizokami A, Ito H, Yatani R, Shiraishi T. Epigenetic regulation of 132. Yang SH, Song CH, Van HT, Park E, Khadka DB, Gong EY, Lee
androgen receptor gene expression in human prostate cancers. Lab K, Cho WJ. SAR based design of nicotinamides as a novel class
Invest 2000;80:1789-96. of androgen receptor antagonists for prostate cancer. J Med Chem
116. Schulz WA, Hoffmann MJ. Epigenetic mechanisms in the biology of 2013;56:3414-8.
prostate cancer. Semin Cancer Biol 2009;19:172-80. 133. Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei
117. Martinez-Ariza G, Hulme C. Recent advances in allosteric androgen A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL,
receptor inhibitors for the potential treatment of castration-resistant Trepel JB, Malhotra SV, Varchi G. 1,4-substituted triazoles as
prostate cancer. Pharm Pat Anal 2015;4:387-402. nonsteroidal anti-androgens for prostate cancer treatment. J Med
118. Lu X, Dun K, Wang Y, Yang Y, You Q, Li Z. Recent androgen receptor Chem 2017;60:3082-93.
antagonists in prostate cancer. Mini Rev Med Chem 2014;14:655-63. 134. Buzon V, Carbo LR, Estruch SB, Fletterick RJ, Estebanez-Perpina
119. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, E. A conserved surface on the ligand binding domain of nuclear
Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen receptors for allosteric control. Mol Cell Endocrinol 2012;348:394-
402.
CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers 135. Estebanez-Perpina E, Arnold LA, Nguyen P, Rodrigues ED,
CL. Development of a second-generation antiandrogen for treatment Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, Guy RK,
of advanced prostate cancer. Science 2009;324:787-90. Webb P, Fletterick RJ. A surface on the androgen receptor that
120. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, allosterically regulates coactivator binding. Proc Natl Acad Sci U S A
Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao 2007;104:16074-9.
G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, 136. Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma
Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass
Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, JP, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A.
Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel Identification of a potent antiandrogen that targets the BF3 site of the
antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494- androgen receptor and inhibits enzalutamide-resistant prostate cancer.
503. Chem Biol 2014;21:1476-85.
121. Fizazi K, Albiges L, Loriot Y, Massard C. ODM-201: a new- 137. Zhang Y, Mantravadi PK, Jobbagy S, Bao W, Koh JT. Antagonizing
generation androgen receptor inhibitor in castration-resistant prostate the androgen receptor with a biomimetic acyltransferase. ACS Chem
cancer. Expert Rev Anticancer Ther 2015;15:1007-17. Biol 2016;11:2797-802.
122. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone 138. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien
prevents androgen receptor binding to chromatin and enhances AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S,
degradation of mutant androgen receptor. Clin Cancer Res Andersen RJ, Sadar MD. An androgen receptor N-terminal domain
2014;20:4075-85. antagonist for treating prostate cancer. J Clin Invest 2013;123:2948-
123. Bastos DA, Antonarakis ES. Galeterone for the treatment of 60.
advanced prostate cancer: the evidence to date. Drug Des Devel Ther 139. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK,
2016;10:2289-97. Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan IJ,
124. Biron E, Bedard F. Recent progress in the development of protein- Wang Y, Sadar MD. Regression of castrate-recurrent prostate cancer
protein interaction inhibitors targeting androgen receptor-coactivator by a small-molecule inhibitor of the amino-terminus domain of the
binding in prostate cancer. J Steroid Biochem Mol Biol 2016;161:36- androgen receptor. Cancer Cell 2010;17:535-46.
44. 140. Antonarakis ES, Antonarakis ES, Luo J, Chandhasin C, Osbourne
125. Ran F, Xing H, Liu Y, Zhang D, Li P, Zhao G. Recent developments in E, Perabo F, Sadar MD. Targeting the N-terminal domain of the

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017 359